Palbociclib/CAS 571190-30-2

Palbociclib (CAS 571190-30-2) is a high-purity pharmaceutical API classified as a selective CDK4/6 inhibitor, featuring a small-molecule pyridopyrimidine structure engineered to target cyclin-dependent kinases 4 and 6. It reversibly binds to CDK4/6, blocking their interaction with cyclin D and inhibiting the G1-to-S phase cell cycle transition—effectively suppressing the proliferation of hormone receptor-positive (HR+) cancer cells. This premium API exhibits high specificity and oral bioavailability, ensuring consistent efficacy in capsule formulations with minimal impact on normal cells.

It caters to the core needs of oncology drug manufacturers, biotech research institutions, and clinical trial suppliers. Widely applied in developing treatments for HR+/HER2- advanced breast cancer, it aligns with the demand for targeted endocrine combination therapies. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, ensuring reliability for clinical and research use. For businesses prioritizing innovative, well-tolerated anticancer solutions, this Palbociclib API serves as a critical raw material for advancing breast cancer therapy research and therapeutic development.